WASHINGTON DC—A new blood test has detected drug-resistant mutations reliably in patients with gastrointestinal stromal tumour (GIST) helping to guide therapy when first-line drugs had failed. This was in a study using the recently approved agent regorafenib. Dr George Demetri of the Dana-Farber Harvard Cancer Center presented findings from the GRID study during the 2013 conference of the American Society for Cancer Research. He told Peter Goodwin why the blood test did better than biopsy testing and about the prospects of treating refractory GIST with rogarafenib.
You may also like...
Geriatric Assessment Improved Outcomes for Older Patients with Cancer 11 Jul, 2018 New Strategies for Preventing ER-Negative Breast Cancer 23 Mar, 2015 Urgent Need To Change Cancer Research Priorities: Global Cancer Fund; Prevention; Surgical Innovation; Trans-National Research 21 Oct, 2009 Prostate cancer screening: French study finds more harm than good from PSA testing 19 Nov, 2013
- Previous story Gene expression and molecular pathways guide head and neck cancer therapies
- Next story Treatment “holidays” to overcome resistance in advanced melanoma?
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014